Moravick takes over as Ketchum healthcare head

Share this article:

Ketchum named Ann Moravick EVP and director, global healthcare and brand advocacy.

Moravick joins the company from Publicis Consultants PR, where she was US CEO.

She is charged with spearheading the growth and expanding the global reach of the agency's healthcare practice by bridging the work of its international offices, and reports to partners Dale Bornstein, director, global practices, and Barri Rafferty, director, New York.

The role of global healthcare director has been vacant at Ketchum since Mark Cater left it early last year to lead APCO Worldwide's healthcare practice.

Before joining Publicis, Moravick spent 18 years at Manning, Selvage & Lee, where she headed the firms London office and global healthcare practice and served as deputy managing director of the New York office. She is also a former board member of WOMMA, the Word of Mouth Marketing Association.

Bornstein said her “integrated approach to healthcare and brand advocacy will serve the evolving needs of our clients and further differentiate Ketchum's healthcare practice from others in the industry. With Ann's diverse experience, both in the US and in Europe, she will prove to be an asset to our healthcare clients as they navigate the global markets.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.